Kirkwood JM - Search Results

1

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.

McLouth LE, Zheng Y, Smith S, Hodi FS, Rao UN, Cohen GI, Amatruda TT, Dakhil SR, Curti BD, Nakhoul I, Chandana SR, Bane CL, Marinier DE, Lee SJ, Sondak VK, Kirkwood JM, Tarhini AA, Wagner LI. McLouth LE, et al. Among authors: kirkwood jm. Qual Life Res. 2023 Jan;32(1):183-196. doi: 10.1007/s11136-022-03226-8. Epub 2022 Aug 27. Qual Life Res. 2023. PMID: 36029412 Free PMC article. Clinical Trial.

2

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. Kirkwood JM, et al. J Clin Oncol. 2000 Jun;18(12):2444-58. doi: 10.1200/JCO.2000.18.12.2444. J Clin Oncol. 2000. PMID: 10856105 Clinical Trial.

3

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.

Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. Kirkwood JM, et al. J Clin Oncol. 2001 May 1;19(9):2370-80. doi: 10.1200/JCO.2001.19.9.2370. J Clin Oncol. 2001. PMID: 11331315 Clinical Trial.

4

Interferon alfa-2a for melanoma metastases.

Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M. Kirkwood JM, et al. Lancet. 2002 Mar 16;359(9310):978-9. doi: 10.1016/S0140-6736(02)08001-7. Lancet. 2002. PMID: 11918944 No abstract available.

5

Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690.

Rao UN, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM. Rao UN, et al. Among authors: kirkwood jm. J Clin Oncol. 2002 Apr 15;20(8):2053-7. doi: 10.1200/JCO.2002.08.024. J Clin Oncol. 2002. PMID: 11956265 Clinical Trial.

6

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.

Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L. Kirkwood JM, et al. J Clin Oncol. 2002 Sep 1;20(17):3703-18. doi: 10.1200/JCO.2002.03.052. J Clin Oncol. 2002. PMID: 12202672 Review.

7

Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.

Kirkwood JM, Tarhini AA. Kirkwood JM, et al. Forum (Genova). 2003;13(2):127-40; quiz 187-8. Forum (Genova). 2003. PMID: 14732880 Review.

8

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U; Eastern Cooperative Oncology Group. Kirkwood JM, et al. Clin Cancer Res. 2004 Mar 1;10(5):1670-7. doi: 10.1158/1078-0432.ccr-1103-3. Clin Cancer Res. 2004. PMID: 15014018 Clinical Trial.

9

Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma?

Tarhini AA, Land S, Gupta A, Kirkwood JM. Tarhini AA, et al. Among authors: kirkwood jm. Nat Clin Pract Oncol. 2005 May;2(5):240-1. doi: 10.1038/ncponc0175. Nat Clin Pract Oncol. 2005. PMID: 16264957 No abstract available.

10

Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b".

Tarhini AA, Shipe-Spotloe J, DeMark M, Agarwala SS, Kirkwood JM. Tarhini AA, et al. Among authors: kirkwood jm. Oncologist. 2006 May;11(5):538-9; author reply 539-40. doi: 10.1634/theoncologist.11-5-538. Oncologist. 2006. PMID: 16720861 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

600 results

Search Page